1.2 OMIM# of the disease 603147.
1.3 Name of the analysed genes or DNA/chromosome segments ALG6.
1.4 OMIM# of the gene 604566.
Mutational spectrum
Twenty-three variants have been reported, including 11 missense variants, 1 nonsense variant, 5 deletion variants, 4 splicing variants, and 1 duplication variant. In one patient, a portion of chromosome 1 including ALG6 was deleted as a de novo event 1-4 (www.lovd.nl/ ALG6). The standard reference sequence indicating reported variants (ENSG00000088035) and a reference for exon numbering (ENST00000371108) can be found at http://www.ensembl.org.
Analytical methods
Sanger sequencing of the 14 coding exons and flanking intronic sequences of the ALG6 gene (NCBI reference sequence: NM_013339.3).
Analytical validation
Sanger sequencing identifies variants in 499% of patients. Deep intronic variants, large deletions and duplications would not be detected using this approach. Novel variants with uncertain pathogenic nature are of course possible.
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) If known to be variable between ethnic groups, please report):
Fifty-four patients have been reported. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] The frequency and the prevalence of the disease are not known. The diagnosis has to be confirmed by mutation analysis of ALG6. Since the DLO analysis is cumbersome, produces sometimes equivocal results, and is only available in very few centers, an upcoming strategy is to subject the DNA to a CDG panel of genes known to be involved in CDG. The identification of the pathogenic variant will permit heterozygote detection in the family, and prenatal diagnosis. 
Diagnostic setting

TEST CHARACTERISTICS
Negative predictive value: 
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case. Close to 100%.
Positive clinical predictive value (lifetime risk to develop the disease if the test is positive)
100%, based on positive serum transferrin isoelectrofocusing screening and ALG6 mutation analysis.
Negative clinical predictive value (probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered. Index case in that family had been tested: 100%. Index case in that family had not been tested: 100%. 3.1.2 Describe the burden of alternative diagnostic methods to the patient The blood sampling for the serum transferrin isoelectrofocusing screening test and that for the mutation analysis is a minor burden to the patient.
CLINICAL UTILITY
3.1.3 How is the cost effectiveness of alternative diagnostic methods to be judged? It differs among countries. In Belgium and The Netherlands the cost of these tests is largely carried by the national assurance organism.
Will disease management be influenced by the result of a genetic test?
No & Yes 2
Therapy (please describe)
Treatment of ALG6-CDG is purely symptomatic.
Prognosis (please describe)
Molecular testing is essential for confirmation of the diagnosis and the genetic counselling of the families concerned. Management (please describe) ALG6-CDG is a multi-system disease with major neurological involvement. Follow-up by a multidisciplinary team is important.
Predictive setting:
The tested person is clinically unaffected but carries an increased risk based on family history (To be answered if in 1.9 'B' was marked.) Knowledge of the diagnosis will stop unnecessary further investigations, and will help the parents in the process of accepting the disease although no curative treatment is available.
